Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cyclacel Pharma (CYCC) Tops Q3 EPS by 8c
November 11, 2020 4:36 PM ESTCyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.47), $0.08 better than the analyst estimate of ($0.55).
We continue to execute on our clinical development plan for fadraciclib and CYC140 in both liquid and solid cancers, said Spiro Rombotis, President and Chief Executive Officer. The recent ENA presentation... More
